Glenmark Recalls 114 Batches Of Low Potassium Drug In The US Over Potentially Deadly Hyperkalemia Risk

MAHWAH, N.J. : While patients with low potassium often need medication to boost levels of the electrolyte in the body, too much of a good thing can cause serious health concerns.

Glenmark Pharmaceuticals on Tuesday said it’s recalling 114 batches of 750mg potassium chloride extended-release capsules thanks to failed dissolution of the product.

Failed dissolution of the capsules could cause patients to develop heightened potassium levels, also known as hyperkalemia, which can result in irregular heartbeat. That side effect can potentially in turn lead to cardiac arrest.

Glenmark’s potassium chloride capsules are used to treat patients with low potassium, or hypokalemia. For patients who consistently use the drug—and especially in those with other underlying health conditions like hypertension, heart failure or kidney dysfunction—there is a “reasonable probably of developing hyperkalemia that may lead to a range of severity of adverse events,” including those that are potentially life-threatening, Glenmark said in a release.

To date, Glenmark says it hasn’t received any reports of elevated potassium levels or serious side effect reports linked to the recall. The company is performing the product pull voluntarily in conjunction with the FDA.

The suspect batches of potassium chloride capsules were shipped out across the U.S. to wholesalers, distributors and retailers, Glenmark said. The lots in question were set to expire between June 2024 and September 2025.

The recall comes a little less than a year after Glenmark extricated itself from a sticky debt situation.

Elsewhere, the threat of hyperkalemia has forced other recalls in the past.

Related Posts

  • Pharma
  • July 13, 2024
  • 117 views
Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Hyderabad: Drugs Control Administration officials seized ‘Dacazee 500 Injection’ (Dacarbazine Injection IP 500 mg), during the raids carried out on 11th and 12th July, 2024, at a medical shop located in…

  • Pharma
  • July 13, 2024
  • 85 views
Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

Kolkata: The Drug Price Control Order (DPCO) 2013, India’s key drug regulation aimed at making essential medicines more affordable, has inadvertently led to a decline in the availability of these…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

EMA Warns Of Anaphylactic Reactions To MS Drug

EMA Warns Of Anaphylactic Reactions To MS Drug

14 Barred Patanjali Products Sold Across Counter At Dedicated Stores

14 Barred Patanjali Products Sold Across Counter At Dedicated Stores

Mumbai: FDA Conducts Raids At Three Different Locations In Vasai, Seized Ayurvedic Drugs Worth Rs 1.41 Crore

Mumbai: FDA Conducts Raids At Three Different Locations In Vasai, Seized Ayurvedic Drugs Worth Rs 1.41 Crore

Telangana DCA Raids 2 Places, Seizes Illegally Stocked And Overpriced Medicines

Telangana DCA Raids 2 Places, Seizes Illegally Stocked And Overpriced Medicines